HEADLINE SCIENCE
An international body of medical scientists in obstetrics and gynecology, endocrinology, and other speciality societies, and other physicians announced the result of a multi-year process to formally change the name of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change, published in May 2026 in The Lancet, aims to address the inaccurate and potentially harmful term polycystic ovary syndrome (PCOS) for multiple reasons, to include risks related to delayed diagnosis, fragmented care, and confusing communication between patients and health professionals, as well as reinforcement of social stigmas related to infertility.Â
The change was driven by international experts, researchers, and patients, led by Prof. Helena Teede at the Monash Centre for Health Research & Implementation out of concern that PMOS affects one in eight women worldwide and covers reproductive, metabolic, and endocrine dysfunctions. Implementation of the new name is being rolled out through a three-year strategy for clinical adoption.
Read the Full Article
For further details, please refer to: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
Source:
Teede H, Khomami M, Morman R et al. (2026) Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. DOI: 10.1016/S0140-6736(26)00717-8